Actinium Pharmaceuticals (NYSE:ATNM) Trading 4.2% Higher – What’s Next?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM)’s stock price shot up 4.2% during mid-day trading on Friday . The stock traded as high as $0.9973 and last traded at $0.99. Approximately 126,338 shares changed hands during mid-day trading, a decline of 17% from the average daily volume of 151,972 shares. The stock had previously closed at $0.95.

Wall Street Analysts Forecast Growth

Separately, Stephens restated an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $5.00.

Actinium Pharmaceuticals Stock Performance

The company has a market capitalization of $31.06 million, a PE ratio of -0.71 and a beta of -0.06. The company’s 50-day moving average is $1.17 and its 200 day moving average is $1.22.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mayport LLC purchased a new stake in Actinium Pharmaceuticals during the 3rd quarter valued at $35,000. AM Investment Strategies LLC bought a new position in shares of Actinium Pharmaceuticals during the fourth quarter valued at $40,000. Qube Research & Technologies Ltd bought a new position in shares of Actinium Pharmaceuticals during the second quarter valued at $70,000. Bailard Inc. bought a new position in shares of Actinium Pharmaceuticals during the fourth quarter valued at $79,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Actinium Pharmaceuticals during the fourth quarter valued at $89,000. 27.50% of the stock is owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.